Cerebral and Cognitive Markers of Treatment Resistance in Obsessive Compulsive Disorder (3TOC)
Cerebral and Cognitive Markers of Treatment Resistance in Obsessive-compulsive Disorder: Towards Personalization of Patient Care
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Damien Doolub, MD
- Phone Number: +33 (0)5 16 61 18
- Email: damien.doolub@ch-poitiers.fr
Study Locations
-
-
-
Poitiers, France
- Recruiting
- Centre Hospitalier Henri Laborit
-
Contact:
- Damien Doolub, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Patients will be recruited from the Clinical Research Unit of Poitiers. All volunteer patients included in this study will be included regardless of the degree of resistance to treatment or the severity of their disease. Patients will not be hospitalized for the duration of the study unless their condition requires it.
Healthy volunteers will be recruited locally by advertisement or through acquaintances, and will be matched to each patient based on age, gender, laterality, and education level. They must not have an acute pathology being treated, nor take psychotropic drugs, nor be followed in psychotherapy. In their history, we must not find hospitalization in a psychiatric environment or a psychiatric illness according to the M.I.N.I. version 5.0.0.
Description
Inclusion Criteria:
- Obsessive compulsive disorder diagnosed according to Diagnostic and Statistical Manual 5 criteria (patients will be included regardless of the severity and resistance of their pathology and their levels of executive functions)
- Understand and accept the constraints of the study
- Be a beneficiary or affiliated to a Health Insurance scheme
Exclusion Criteria:
- Present one of the diagnoses according to the criteria of the DSM 5: schizophrenic disorders, substance abuse or dependence to a substance according to the criteria of the M.I.N.I. version 5.0 (Sheehan et al., 1998)
- Generalized anxiety disorder, social anxiety, nicotine dependence and history of a major depressive episode are not exclusion criteria according to the M.I.N.I. version 5.0 (Sheehan et al., 1998)
- Have a serious intercurrent pathology
- Being a pregnant woman
- Being a woman of childbearing age without effective contraception.
- Being hospitalized under duress or on an outpatient basis in a care program
- Being under judicial protection (reinforced curatorship, guardianship)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Control Patients
|
Three cognitive tests will be performed in the MRI, namely a stroop task, an N-back task and a switching task
|
|
obsessive compulsive disorder patients
|
Three cognitive tests will be performed in the MRI, namely a stroop task, an N-back task and a switching task
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cerebral activity modification during N-back task
Time Frame: Day 1
|
Blood-oxygen-level-dependent (BOLD) modification during the task between obsessive compulsive disorder patients and controls
|
Day 1
|
|
Cerebral activity modification during Stroop task
Time Frame: Day 1
|
Blood-oxygen-level-dependent (BOLD) modification during the task between obsessive compulsive disorder patients and controls
|
Day 1
|
|
Cerebral activity modification during switching task (Monsell et Mizon task )
Time Frame: Day 1
|
Blood-oxygen-level-dependent (BOLD) modification during the task between obsessive compulsive disorder patients and controls
|
Day 1
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2022-A00463-40
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.